In clinical studies of dapagliflozin and canagliflozin, decreased 8-hydroxy-2-deoxyguanosine (8-OHdG) and oxidized low-density lipoprotein (ox-LDL) levels in patients with T2DM further corroborated the antioxidant effects of SGLT2 inhibitors [39,61]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.